AAPL327.46+2.50 (+0.77%) ▲|ABBV260.94-0.78 (-0.30%) ▼|ABT108.42-2.05 (-1.86%) ▼|ACN193.77+6.09 (+3.24%) ▲|ADBE285.34+5.55 (+1.98%) ▲|AMAT435.64-2.82 (-0.64%) ▼|AMD456.72-0.34 (-0.07%) ▼|AMGN442.96+0.12 (+0.03%) ▲|AMT178.11+5.19 (+3.00%) ▲|AMZN258.46+3.48 (+1.36%) ▲|AVGO358.20-9.04 (-2.46%) ▼|AXP330.43+0.45 (+0.14%) ▲|BA210.45+1.58 (+0.76%) ▲|BAC63.15+0.55 (+0.88%) ▲|BKNG195.95-3.65 (-1.83%) ▼|BLK1,121.69+14.61 (+1.32%) ▲|BMY67.68+0.02 (+0.02%) ▲|BNY164.06+2.02 (+1.25%) ▲|BRK-B507.69+2.45 (+0.48%) ▲|C138.22+3.88 (+2.88%) ▲|CAT794.72+2.44 (+0.31%) ▲|CL89.94-0.16 (-0.18%) ▼|CMCSA26.65-0.17 (-0.62%) ▼|COF220.72+4.12 (+1.90%) ▲|COP135.89-1.31 (-0.95%) ▼|COST928.12-0.36 (-0.04%) ▼|CRM265.47+8.54 (+3.32%) ▲|CSCO108.83-0.63 (-0.57%) ▼|CVS96.89-0.34 (-0.35%) ▼|CVX211.82+0.04 (+0.02%) ▲|DE686.59-11.78 (-1.69%) ▼|DHR210.43+0.52 (+0.25%) ▲|DIS107.35-0.63 (-0.58%) ▼|DUK121.50+0.94 (+0.78%) ▲|EMR150.08+1.10 (+0.74%) ▲|FDX322.88+6.34 (+2.00%) ▲|GD364.10+0.03 (+0.01%) ▲|GE332.68+3.18 (+0.96%) ▲|GEV940.50+18.56 (+2.01%) ▲|GILD150.83+1.22 (+0.82%) ▲|GM87.02+2.15 (+2.53%) ▲|GOOG339.67+5.89 (+1.76%) ▲|GOOGL343.02+5.90 (+1.75%) ▲|GS1,035.87+31.45 (+3.13%) ▲|HD318.02+1.84 (+0.58%) ▲|HON207.47+1.40 (+0.68%) ▲|IBM233.06+1.36 (+0.59%) ▲|INTC91.07+1.02 (+1.13%) ▲|INTU346.71+3.77 (+1.10%) ▲|ISRG370.58-1.31 (-0.35%) ▼|JNJ278.18+2.97 (+1.08%) ▲|JPM362.35+6.13 (+1.72%) ▲|KO89.11+0.87 (+0.98%) ▲|LIN482.68-3.18 (-0.65%) ▼|LLY1,155.47-4.61 (-0.40%) ▼|LMT531.36-0.19 (-0.04%) ▼|LOW202.71+2.87 (+1.44%) ▲|LRCX290.89+2.57 (+0.89%) ▲|MA584.95-3.19 (-0.54%) ▼|MCD259.62-1.33 (-0.51%) ▼|MDLZ61.39-1.07 (-1.71%) ▼|MDT92.46+0.28 (+0.30%) ▲|META613.49+20.64 (+3.48%) ▲|MMM168.13-0.63 (-0.37%) ▼|MO69.78+0.22 (+0.31%) ▲|MRK151.65+0.01 (+0.01%) ▲|MS217.00+5.18 (+2.44%) ▲|MSFT511.22+14.40 (+2.90%) ▲|MU947.50-8.58 (-0.90%) ▼|NEE84.09+0.99 (+1.19%) ▲|NFLX82.69-0.05 (-0.05%) ▼|NKE38.76+0.52 (+1.36%) ▲|NOW145.75+9.03 (+6.60%) ▲|NVDA229.46+5.05 (+2.25%) ▲|ORCL155.64+9.89 (+6.78%) ▲|PEP140.32-0.20 (-0.14%) ▼|PFE28.72-0.30 (-1.03%) ▼|PG147.30-0.34 (-0.23%) ▼|PLTR183.78+14.32 (+8.45%) ▲|PM187.37-0.57 (-0.30%) ▼|QCOM169.38+0.34 (+0.20%) ▲|RTX201.69+0.91 (+0.45%) ▲|SBUX106.01-0.72 (-0.67%) ▼|SCHW110.64+2.40 (+2.22%) ▲|SO88.97+0.66 (+0.74%) ▲|SPG211.46+1.26 (+0.60%) ▲|T26.16+0.21 (+0.79%) ▲|TMO616.47+7.93 (+1.30%) ▲|TMUS188.54+1.24 (+0.66%) ▲|TSLA380.80+23.79 (+6.66%) ▲|TXN252.80-2.00 (-0.78%) ▼|UBER75.85-0.60 (-0.78%) ▼|UNH400.39+0.73 (+0.18%) ▲|UNP290.09+0.36 (+0.12%) ▲|UPS103.38+0.37 (+0.36%) ▲|USB63.57+0.80 (+1.27%) ▲|V378.60+0.20 (+0.05%) ▲|VZ50.65+0.43 (+0.85%) ▲|WFC89.15-0.13 (-0.14%) ▼|WMT108.75+2.66 (+2.51%) ▲|XOM162.76-1.39 (-0.85%) ▼|AAPL327.46+2.50 (+0.77%) ▲|ABBV260.94-0.78 (-0.30%) ▼|ABT108.42-2.05 (-1.86%) ▼|ACN193.77+6.09 (+3.24%) ▲|ADBE285.34+5.55 (+1.98%) ▲|AMAT435.64-2.82 (-0.64%) ▼|AMD456.72-0.34 (-0.07%) ▼|AMGN442.96+0.12 (+0.03%) ▲|AMT178.11+5.19 (+3.00%) ▲|AMZN258.46+3.48 (+1.36%) ▲|AVGO358.20-9.04 (-2.46%) ▼|AXP330.43+0.45 (+0.14%) ▲|BA210.45+1.58 (+0.76%) ▲|BAC63.15+0.55 (+0.88%) ▲|BKNG195.95-3.65 (-1.83%) ▼|BLK1,121.69+14.61 (+1.32%) ▲|BMY67.68+0.02 (+0.02%) ▲|BNY164.06+2.02 (+1.25%) ▲|BRK-B507.69+2.45 (+0.48%) ▲|C138.22+3.88 (+2.88%) ▲|CAT794.72+2.44 (+0.31%) ▲|CL89.94-0.16 (-0.18%) ▼|CMCSA26.65-0.17 (-0.62%) ▼|COF220.72+4.12 (+1.90%) ▲|COP135.89-1.31 (-0.95%) ▼|COST928.12-0.36 (-0.04%) ▼|CRM265.47+8.54 (+3.32%) ▲|CSCO108.83-0.63 (-0.57%) ▼|CVS96.89-0.34 (-0.35%) ▼|CVX211.82+0.04 (+0.02%) ▲|DE686.59-11.78 (-1.69%) ▼|DHR210.43+0.52 (+0.25%) ▲|DIS107.35-0.63 (-0.58%) ▼|DUK121.50+0.94 (+0.78%) ▲|EMR150.08+1.10 (+0.74%) ▲|FDX322.88+6.34 (+2.00%) ▲|GD364.10+0.03 (+0.01%) ▲|GE332.68+3.18 (+0.96%) ▲|GEV940.50+18.56 (+2.01%) ▲|GILD150.83+1.22 (+0.82%) ▲|GM87.02+2.15 (+2.53%) ▲|GOOG339.67+5.89 (+1.76%) ▲|GOOGL343.02+5.90 (+1.75%) ▲|GS1,035.87+31.45 (+3.13%) ▲|HD318.02+1.84 (+0.58%) ▲|HON207.47+1.40 (+0.68%) ▲|IBM233.06+1.36 (+0.59%) ▲|INTC91.07+1.02 (+1.13%) ▲|INTU346.71+3.77 (+1.10%) ▲|ISRG370.58-1.31 (-0.35%) ▼|JNJ278.18+2.97 (+1.08%) ▲|JPM362.35+6.13 (+1.72%) ▲|KO89.11+0.87 (+0.98%) ▲|LIN482.68-3.18 (-0.65%) ▼|LLY1,155.47-4.61 (-0.40%) ▼|LMT531.36-0.19 (-0.04%) ▼|LOW202.71+2.87 (+1.44%) ▲|LRCX290.89+2.57 (+0.89%) ▲|MA584.95-3.19 (-0.54%) ▼|MCD259.62-1.33 (-0.51%) ▼|MDLZ61.39-1.07 (-1.71%) ▼|MDT92.46+0.28 (+0.30%) ▲|META613.49+20.64 (+3.48%) ▲|MMM168.13-0.63 (-0.37%) ▼|MO69.78+0.22 (+0.31%) ▲|MRK151.65+0.01 (+0.01%) ▲|MS217.00+5.18 (+2.44%) ▲|MSFT511.22+14.40 (+2.90%) ▲|MU947.50-8.58 (-0.90%) ▼|NEE84.09+0.99 (+1.19%) ▲|NFLX82.69-0.05 (-0.05%) ▼|NKE38.76+0.52 (+1.36%) ▲|NOW145.75+9.03 (+6.60%) ▲|NVDA229.46+5.05 (+2.25%) ▲|ORCL155.64+9.89 (+6.78%) ▲|PEP140.32-0.20 (-0.14%) ▼|PFE28.72-0.30 (-1.03%) ▼|PG147.30-0.34 (-0.23%) ▼|PLTR183.78+14.32 (+8.45%) ▲|PM187.37-0.57 (-0.30%) ▼|QCOM169.38+0.34 (+0.20%) ▲|RTX201.69+0.91 (+0.45%) ▲|SBUX106.01-0.72 (-0.67%) ▼|SCHW110.64+2.40 (+2.22%) ▲|SO88.97+0.66 (+0.74%) ▲|SPG211.46+1.26 (+0.60%) ▲|T26.16+0.21 (+0.79%) ▲|TMO616.47+7.93 (+1.30%) ▲|TMUS188.54+1.24 (+0.66%) ▲|TSLA380.80+23.79 (+6.66%) ▲|TXN252.80-2.00 (-0.78%) ▼|UBER75.85-0.60 (-0.78%) ▼|UNH400.39+0.73 (+0.18%) ▲|UNP290.09+0.36 (+0.12%) ▲|UPS103.38+0.37 (+0.36%) ▲|USB63.57+0.80 (+1.27%) ▲|V378.60+0.20 (+0.05%) ▲|VZ50.65+0.43 (+0.85%) ▲|WFC89.15-0.13 (-0.14%) ▼|WMT108.75+2.66 (+2.51%) ▲|XOM162.76-1.39 (-0.85%) ▼|
29.8 C
New York
Thursday, September 3, 2026

Tag: tumor

newssourceFORcompanyinformationcontent1releasesmarket

BioDlink Drives Global Biologics Innovation with Ecosystem Partners

BioDlink convenes a peer advisory event bringing together biotech CEOs, MNC leaders and researchers to discuss innovation and collaboration strategiesIntegrated one-stop technology platform helps...

Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai

SHANGHAI, July 4, 2025 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma...

Adverse events were generally low-grade, transient, and readily manageable

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

BENGALURU, India, July 3, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that...

Jacobio’s IND for Phase I/II Clinical Trial of BET Inhibitor JAB-8263 in Autoimmune Diseases has been Accepted

BEIJING, SHANGHAI and BOSTON, July 2, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that it has submitted the Phase I/II Investigational New Drug (IND)...

Dizal’s ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20insApproval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which...

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2025, the company granted non-qualified stock options to purchase 10,700 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

Block O’Toole & Murphy Raises Over $1,375,000 for St. Jude’s Hospital at Annual New York City Wine Tasting Event

NEW YORK, July 2, 2025 /PRNewswire/ -- New York personal injury law firm Block O'Toole & Murphy is honored to share that the firm raised...

I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025

Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

Lynozyfic is a bispecific antibody directing T cells to kill multiple myeloma cancer cells; multiple myeloma is the second most common blood cancer 

SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response

SAN DIEGO, July 2, 2025 /PRNewswire/ -- A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately...

Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation...

Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H)...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTumor

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers